source
- GSK cuts deal with Sino to broaden reach of hepatitis B drugThe marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access to a therapy called bepirovirsen that’s important to its future.BioPharma Dive · 3mo ago↗ source
- STAT+: Astellas treatment offers new hope to a devastated rare disease communityAlzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The ReadoutSTAT · 3mo ago↗ source
- Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trialInhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.